T cell Isolation from PBMCs

using 50nm Superparamagnetic IngenuityTM Beads

Advancing T Cell Isolation for CAR T Cell Therapy with Column-Free Technology

The therapeutic efficacy of CAR T cells in hematologic malignancies underscores the urgency for a cost-effective manufacturing process. T cell isolation, a crucial upstream step, significantly influences T cell quality and therapy success. 50nm superparamagnetic particles offer superior efficiency and eliminate downstream removal needs. Despite their clinical traction, existing options often rely on cumbersome column-based separation methods. Applied Cells IngenuityTM 50nm beads with proprietary column-free technology in MARS® Bar automates and streamlines T cell isolation, promising enhanced efficiency and scalability for CAR T cell therapy.

T cell Isolation

Efficient Isolation of T Cells from PBMCs using the MARS® Bar Platform, with No Compromise in Viability.

Utilizing the MARS® Bar platform technology, researchers can reliably separate T cells of high purity and yield. Panel A represents peripheral blood mononuclear cells (PBMC) before the separation process, while Panel B showcases T cells enriched from PBMCs using IngenuityTM 50nm beads.

Starting from an initial average T cell purity of 49.92%, T cell positive selection was performed with the IngenuityTM 50nm CD4 and CD8 beads on the MARS® Bar system, resulting in an average recovery rate of 75.31% T cells with a mean purity of 91.68% (A, n= 12 samples).

Viability assessment before and after positive selection (B) revealed no significant impact (P<0.5) on cell viability, ensuring the integrity of T cells across the isolation process.

Robust Expansion of T Cells Enriched by IngenuityTM 50nm Beads Using MARS® Bar

T cells, enriched by IngenuityTM 50nm beads using the MARS® Bar platform, showed robust expansion in subsequent cell culture. The enriched T cells proliferated significantly, expanding over 112-fold by day 10 post-enrichment, following culturing the cells in T cell expansion medium supplemented with CD3/CD28 activator on standard cell culture plates. The substantial growth observed underscores the efficacy of T cell enrichment using Applied Cells’ workflow and highlights the potential for downstream applications in cellular therapies.

Download the new Application note

The effectiveness of CAR T cell therapy in treating hematologic malignancies is well-established. However, widespread adoption of this therapy hinges on developing a cost-effective manufacturing process. Download the App Note demonstrating T cell isolation using Applied Cells IngenuityTM 50nm beads, our proprietary column-free technology integrated into the closed automated system MARS® Bar revolutionizes this process.

Explore other MARS® Platform Applications

tumor cell

Target Cell Isolation

Choose one of MARS gentle, centrifuge-free and Ficoll-free workflows for immunoselection of TIL, T Cells, NK cells Neutrophils or Stem cells.

Learn More

Explore other MARS® Platform Applications

Cell and Nuclei Enrichment

Easy and fast debris removal to feed genomic platforms with enriched cells from samples including Whole Blood, tumor, PMBC, solid tissue and many others.

Learn More

Contact us and Redefine Your Cell Isolation Workflow!